Deferasirox and Selexipag

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 2C8 may increase exposure to the active metabolite of selexipag. Selexipag and its active metabolite are both metabolized mainly via CYP450 2C8. Coadministration of selexipag with clopidogrel (300 mg loading dose or 75 mg once daily maintenance dose) had no relevant effect on exposure to selexipag but increased exposure to the active metabolite by approximately 2.2 and 2.7-fold following the loading and maintenance doses, respectively. MANAGEMENT: The dosing frequency of selexipag should be reduced to once daily if coadministered with a moderate CYP450 2C8 inhibitor. If the moderate CYP450 2C8 inhibitor is withdrawn from therapy, the selexipag dosing frequency should return to twice daily. Clinical and laboratory monitoring of selexipag should be considered whenever a moderate CYP450 2C8 inhibitor is added to or withdrawn from therapy. Patients should be monitored for potentially increased side effects such as diarrhea, nausea, vomiting, flushing, anemia, and decreased appetite. References "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc, South San Francisco, CA. Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Plavix (clopidogrel)." Bristol-Myers Squibb, Princeton, NJ. View all 4 references

ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 2C8 may increase exposure to the active metabolite of selexipag. Selexipag and its active metabolite are both metabolized mainly via CYP450 2C8. Coadministration of selexipag with clopidogrel (300 mg loading dose or 75 mg once daily maintenance dose) had no relevant effect on exposure to selexipag but increased exposure to the active metabolite by approximately 2.2 and 2.7-fold following the loading and maintenance doses, respectively.

MANAGEMENT: The dosing frequency of selexipag should be reduced to once daily if coadministered with a moderate CYP450 2C8 inhibitor. If the moderate CYP450 2C8 inhibitor is withdrawn from therapy, the selexipag dosing frequency should return to twice daily. Clinical and laboratory monitoring of selexipag should be considered whenever a moderate CYP450 2C8 inhibitor is added to or withdrawn from therapy. Patients should be monitored for potentially increased side effects such as diarrhea, nausea, vomiting, flushing, anemia, and decreased appetite.

Deferasirox

Generic Name: deferasirox

Brand name: Exjade, Jadenu, Jadenu Sprinkle

Synonyms: n.a.

What is Deferasirox?

Selexipag

Generic Name: selexipag

Brand name: Uptravi, Uptravi Titration Pack

Synonyms: n.a.

What is Selexipag?